AstraZeneca Highlights R&D Growth Strategy via Collaborations with BIND Therapeutics and Horizon Discovery
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 29 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1928 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AstraZeneca has partnered with BIND Therapeutics in a deal potentially worth US$199 M to use the company’s Medicinal Nanoengineering® platform to develop and commercialise an Accurin™, a targeted and programmable nanomedicine, based on a molecularly targeted kinase inhibitor developed by AstraZeneca...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS